AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%
AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...
AbbVie retains Humira market share above 70%: report
AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the blockbuster ...
pharmaphorum11d
So it begins: Next Humira biosimilars launch in US
This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many ... aiming to cut injection volume by half and result in fewer injections in particular ...
Seeking Alpha21d
AbbVie keeps Humira lead as biosimilar entry nears two-year mark
AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70% ... The anti-inflammatory injection, also known as adalimumab, lost its U.S ...
Morningstar7d
AbbVie's Skyrizi and Rinvoq Have Revived Growth Beyond Humira, Supporting a Wide Moat
AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term ...